Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Invivyd, Inc. - Common Stock (NQ:IVVD)

0.7351 +0.0121 (+1.67%)
Streaming Delayed Price Updated: 1:00 PM EDT, Jul 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Invivyd, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Invivyd and Leading Researchers Form SPEAR (Spike Protein Elimination and Recovery) Study Group to Assess the Effects of Monoclonal Antibody Therapy for Long COVID and COVID-19 Post-Vaccination Syndrome
From Invivyd
Via GlobeNewswire
Invivyd Announces Positive Full Phase 1/2 Clinical Data for VYD2311, a Next Generation COVID-19 Monoclonal Antibody for Potential Use as a Non-Vaccine Preventative and for Treatment of Active Infection
From Invivyd
Via GlobeNewswire
What to Expect from Invivyd's Earnings
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Invivyd Announces Publication of Landmark CANOPY Phase 3 PEMGARDA® (pemivibart) Clinical Trial; Results Underscore Strong Efficacy of Monoclonal Antibodies in Preventing COVID-19 in a Modern U.S. Population Against Relevant, Immune-Evasive SARS-CoV-2
From Invivyd
Via GlobeNewswire
Invivyd Announces Inclusion of PEMGARDA® (pemivibart) in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for B-Cell Lymphomas
From Invivyd
Via GlobeNewswire
Invivyd Commends FDA Focus on Contemporary Evidence In Evaluating Medical Interventions To Prevent COVID-19
From Invivyd
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Invivyd Reports First Quarter 2025 Financial Results and Recent Business Highlights
From Invivyd
Via GlobeNewswire
Earnings Scheduled For May 15, 2025
Via Benzinga
Invivyd Files Citizen Petition Urging FDA to Focus on Monoclonal Antibodies For Endemic-Virus-Era COVID-19 Prevention, and to Re-Assess COVID-19 Vaccine Efficacy
From Invivyd
Via GlobeNewswire
There are notable gap-ups and gap-downs in today's session.
Let's delve into the US markets on Tuesday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks. 
Via Chartmill
Invivyd to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference
From Invivyd
Via GlobeNewswire
Invivyd Launches New Measles Antibody Discovery Program: Retail Traders Bet On ‘Future Of Medicine’
Invivyd unveiled a discovery program for a measles-targeted monoclonal antibody, responding to provider demand amid a lack of approved treatments or post-exposure options. 
Via Stocktwits
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Invivyd Announces New Pipeline Discovery Program Focused on Monoclonal Antibody Treatment for Measles
From Invivyd
Via GlobeNewswire
Invivyd to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025
From Invivyd
Via GlobeNewswire
Wednesday's session: top gainers and losers
Curious to know what's happening on the US markets in the middle of the day on Wednesday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
What's Going On With Invivyd Stock On Monday?
Invivyd, Inc. (NASDAQ: IVVD) secures $30M loan facility with Silicon Valley Bank for future capital drawdowns and aims for near-term profitability. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Invivyd Announces $30M Non-dilutive Loan Facility with Silicon Valley Bank
From Invivyd
Via GlobeNewswire
Invivyd Appoints Ajay Royan, Founder of Mithril Capital, to its Board of Directors
From Invivyd
Via GlobeNewswire
Invivyd Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Recent Business Highlights
From Invivyd
Via GlobeNewswire
Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Currently Dominant SARS-CoV-2 Variant LP.8.1
From Invivyd
Via GlobeNewswire
Top movers in Monday's session
Intrigued by the market activity one hour before the close of the markets on Monday? Uncover the key winners and losers of today's session in our insightful analysis. 
Via Chartmill
These stocks are moving in today's session
Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements. 
Via Chartmill
There are notable gap-ups and gap-downs in today's session.
The market is buzzing with gapping stocks on Monday. Let's uncover which stocks are experiencing notable gaps during today's session. 
Via Chartmill
Wondering what's happening in today's pre-market session?
As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses. 
Via Chartmill
FDA Rejects Invivyd's Request To Expand Emergency Authorization For Preventive COVID-19 Antibody For Immunocompromised Patients
Invivyd's bid to expand Pemgarda's EUA for COVID-19 treatment was denied by the FDA. The company will share new data on pemivibart and VYD2311 soon. 
Via Benzinga
FDA Declined Invivyd’s Request to Expand Existing Emergency Use Authorization of PEMGARDA™ (pemivibart) to Include Treatment of Mild-to-Moderate COVID-19 For Immunocompromised Persons Who Have No Alternative Therapeutic Options; No Change to the Existing
From Invivyd
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.